Coeptis Therapeutics, a publicly traded biopharmaceutical company, has announced a merger agreement with Z Squared Inc., a digital asset miner focused on Dogecoin. The merger, expected to close in Q3 2025, aims to create the largest publicly traded Dogecoin mining company in the United States. As part of the deal, Coeptis will spin off its biopharmaceutical operations, which focus on cell therapies for cancer, autoimmune, and infectious diseases, into a separate private entity. The combined public entity will rebrand as Z Squared Inc. and focus entirely on Dogecoin mining, utilizing 9,000 mining machines. Z Squared will become a wholly owned subsidiary of Coeptis. The boards of both companies have approved the merger, which remains subject to regulatory and shareholder approval. Following the announcement, shares of Coeptis fell nearly 40% to $7.53, though they remain up 37% year-to-date. Z Squared CEO David Halabu will lead the merged company, which will continue trading on the Nasdaq. Halabu stated, "We are excited to take this step towards our goal of creating the largest publicly-traded company in the United States primarily focused on DOGE mining." Coeptis CEO Dave Mehalick added, "We are excited to bring this opportunity to our shareholders to become involved in the Dogecoin market space." The company may also consider expanding into Litecoin mining and other digital asset strategies in the future. Dogecoin is currently trading above $0.18, up 1.3% in the last 24 hours and 16% over the week, with a market capitalization of nearly $28 billion. Four Dogecoin-focused exchange-traded fund applications are awaiting approval from the U.S. Securities and Exchange Commission.